Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190630 | 0.91 | GRM5 (0.62) | GRM5ITGB3ITGA2BALDH1A1MAPT | |
| SCHEMBL10190631 | 0.89 | GRM5 (0.64) | GRM5ITGB3ITGA2BCHRM2CHRM4 | |
| SCHEMBL8167486 | 0.88 | GRM5 (0.67) | GRM5ITGB3ITGA2B | |
| SCHEMBL504633 | 0.87 | GRM5 (0.70) | GRM5ITGB3ITGA2BALDH1A1MAPT | |
| SCHEMBL10242687 | 0.84 | HRH3 (0.55) | ALDH1A1MAPT | |
| SCHEMBL504310 | 0.83 | GRM5 (0.78) | GRM5ITGB3ITGA2B | |
| SCHEMBL10190620 | 0.82 | GRM5 (0.71) | GRM5ITGB3ITGA2B | |
| SCHEMBL504362 | 0.82 | ITGB3 (0.69) | GRM5ITGB3ITGA2B | |
| SCHEMBL504289 | 0.80 | GRM5 (0.65) | GRM5ITGB3ITGA2BFFAR1 | |
| SCHEMBL505111 | 0.79 | GRM5 (0.69) | GRM5ITGB3ITGA2BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028955-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-20120028955-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-20120028956-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-20120028956-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| US-8034806-B2 | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034806-B2 | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2011-10-11 | — | — | US | disclosed |
| EP-2162136-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2009-10-29 | — | — | US | disclosed |
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2009-10-29 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028955-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM1 | GRM5 1/4885ITGB3 4725/4885ITGA2B 4781/4885 |
| US-20120028956-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM1 | GRM5 1/4885ITGB3 4725/4885ITGA2B 4781/4885 |
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM1 | GRM5 1/4885ITGB3 4725/4885ITGA2B 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.